Dermal and epidermal remodeling using botulinum toxin type A for facial, nonreducible, hyperkinetic lines: Two case studies

Journal of Cosmetic Dermatology

Volumn 7, Issue 3, 2008, Pages 241-244

  Bowler, Patrick J ^a  

^a Court House Clinic ^*  (United Kingdom)

Author keywords

BOTOX ; Botulinum toxin type A; Gyperkinetic facial lines; Long term treatment; Subject satisfaction

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; FACE; FEMALE; FOREHEAD; HUMAN; HYPERFUNCTIONAL NONREDUCIBLE FACIAL LINE; LONG TERM CARE; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; TREATMENT DURATION; WRINKLE;

BOTULINUM TOXIN TYPE A; DERMIS; EPIDERMIS; FACE; FEMALE; FOREHEAD; HUMANS; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PATIENT SATISFACTION; REJUVENATION; SKIN AGING; TREATMENT OUTCOME;

EID: 48949099556     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/j.1473-2165.2008.00399.x     Document Type: Article

References (10)

1. Finn CJ, Cox SE, Earl ML. Social implications of hyperfunctional facial lines. Dermatol Surg 2003; 29: 450-5.
2. Carruthers A, Carruthers J. History of the cosmetic use of botulinum A exotoxin. Dermatol Surg 1998; 24: 1168-70.
3. Carruthers A, Carruthers J, Cohen J. A prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in female subjects with horizontal forehead rhytides. Dermatol Surg 2003; 29: 461-7.
4. Niamtu J III. Botulinum toxin A: A review of 1085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg 2003; 61: 317-24.
5. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005; 20: 592-7.
6. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006; 13 (4): 35-40.
7. Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J (for the BOTOX ® Glabellar Lines Study Group). One-year, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines: Four-month, double-blind, placebo-controlled period followed by an eight-month, open-label period. American Academy of Dermatology annual conference, Washington DC, March 2001.
8. Bowler P. A retrospective study in the use of botulinum toxin type - A in a UK multidisciplinary cosmetic practice. J Cosmetic Dermatol 2005; 4: 89-92.
9. Carruthers A, Carruthers J. Botulinum toxin type A for treating glabellar lines in men: A dose-ranging study. American Academy of Dermatology annual conference, San Francisco, California, March 22-24, 2003.
10. Bosset S, Barré P, Chalon A et al. Skin ageing: Clinical and histopathologic study of permanent and reducible wrinkles. Eur J Dermatol 2002; 12: 247-52.